Payment overview · 2025
General Payments
$1,885.98
95 reported records · 22 companies
Healthcare provider profile · identity verified
Stephen Thomas Walker, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · ELKIN, NC · NPI 1265402572
Verified facts
What the public records show
CMS Open Payments records show Stephen Thomas Walker, M.D. received $1,885.98 in general payments during 2025 across 95 reported records.
Novo Nordisk Inc accounted for 18.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 45 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Gemtesa, Jardiance, Kerendia, Mounjaro, Ozempic, Rybelsus, Shingrix, Trelegy Ellipta, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 112 claims for Farxiga by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Kerendia by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 113 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 99 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 155 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Paxlovid by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $342.73 | 18.2% | 11 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $277.95 | 14.7% | 13 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $245.09 | 13.0% | 10 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $182.88 | 9.7% | 12 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $150.67 | 8.0% | 7 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $141.52 | 7.5% | 12 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $96.09 | 5.1% | 5 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $94.27 | 5.0% | 6 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $38.15 | 2.0% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $34.84 | 1.9% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $33.02 | 1.8% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $31.51 | 1.7% | 2 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $26.87 | 1.4% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $24.85 | 1.3% | 1 | 2025 |
| Corium, LLC | Unresolved — no canonical attribution shown | $24.73 | 1.3% | 2 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $23.85 | 1.3% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $22.74 | 1.2% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $21.65 | 1.1% | 1 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $21.42 | 1.1% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $20.27 | 1.1% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $20.20 | 1.1% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $10.68 | 0.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,885.98 | 95 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $272.74 | 6 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $248.44 | 11 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $154.83 | 5 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $150.67 | 7 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $146.78 | 10 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $125.90 | 11 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $112.03 | 10 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $109.48 | 8 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $96.32 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $95.06 | 7 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $94.27 | 6 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $76.43 | 4 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $57.46 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $51.61 | 4 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $49.60 | 3 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $38.15 | 2 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $34.84 | 2 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $34.84 | 2 | 2025 |
Source payment records
|
|||||
| ROTATEQ Normalized: rotateq |
Biological | Merck Sharp & Dohme LLC | $34.84 | 2 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $34.84 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $33.02 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $31.51 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $29.51 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $29.51 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $29.51 | 2 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $26.87 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $24.85 | 1 | 2025 |
Source payment records
|
|||||
| Azstarys Normalized: azstarys |
Drug | Corium, LLC | $24.73 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $24.52 | 2 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $23.85 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $22.74 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $21.65 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $21.62 | 1 | 2025 |
Source payment records
|
|||||
| BEYFORTUS Normalized: beyfortus |
Biological | SANOFI PASTEUR INC. | $21.42 | 1 | 2025 |
Source payment records
|
|||||
| FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE Normalized: flublok quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $21.42 | 1 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $20.27 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $20.20 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $19.69 | 1 | 2025 |
Source payment records
|
|||||
| BEXSERO Normalized: bexsero |
Biological | GlaxoSmithKline, LLC. | $19.66 | 1 | 2025 |
Source payment records
|
|||||
| PEDIARIX Normalized: pediarix |
Biological | GlaxoSmithKline, LLC. | $19.66 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $19.66 | 1 | 2025 |
Source payment records
|
|||||
| ENFLONSIA Normalized: enflonsia |
Drug | Merck Sharp & Dohme LLC | $19.60 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $15.62 | 1 | 2025 |
Source payment records
|
|||||
| VAXELIS Normalized: vaxelis |
Biological | Merck Sharp & Dohme LLC | $15.24 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $10.68 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 112 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 99 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 34 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 73 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 155 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 38 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 37 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
43 | 12 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
112 | 17 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
113 | 113 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
38 | 30 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
99 | 22 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
73 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
155 | 23 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
84 | 17 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
15 | 15 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 484 | 116 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 373 | 95 |
| Atorvastatin Calcium | Atorvastatin Calcium | 267 | 71 |
| Omeprazole | Omeprazole | 258 | 68 |
| Amlodipine Besylate | Amlodipine Besylate | 247 | 67 |
| Gabapentin | Gabapentin | 226 | 53 |
| Losartan Potassium | Losartan Potassium | 226 | 49 |
| Pantoprazole Sodium | Pantoprazole Sodium | 216 | 55 |
| Potassium Chloride | Potassium Chloride | 191 | 46 |
| Metoprolol Succinate | Metoprolol Succinate | 186 | 47 |
| Prednisone | Prednisone | 178 | 110 |
| Zolpidem Tartrate | Zolpidem Tartrate | 177 | 28 |
| Metformin Hcl | Metformin Hcl | 167 | 47 |
| Tamsulosin Hcl | Tamsulosin Hcl | 166 | 42 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 159 | 39 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 158 | 26 |
| Ozempic | Semaglutide | 155 | 23 |
| Tramadol Hcl | Tramadol Hcl | 155 | 35 |
| Citalopram Hbr | Citalopram Hydrobromide | 151 | 34 |
| Simvastatin | Simvastatin | 146 | 39 |
| Lisinopril | Lisinopril | 144 | 40 |
| Lorazepam | Lorazepam | 144 | 31 |
| Furosemide | Furosemide | 140 | 43 |
| Montelukast Sodium | Montelukast Sodium | 132 | 30 |
| Fluticasone Propionate | Fluticasone Propionate | 129 | 41 |
| Hydrochlorothiazide | Hydrochlorothiazide | 124 | 33 |
| Sertraline Hcl | Sertraline Hcl | 114 | 27 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 113 | 113 |
| Farxiga | Dapagliflozin Propanediol | 112 | 17 |
| Celecoxib | Celecoxib | 109 | 34 |
| Finasteride | Finasteride | 103 | 25 |
| Jardiance | Empagliflozin | 99 | 22 |
| Duloxetine Hcl | Duloxetine Hcl | 98 | 23 |
| Cefuroxime | Cefuroxime Axetil | 97 | 75 |
| Clonazepam | Clonazepam | 93 | 17 |
| Metoprolol Tartrate | Metoprolol Tartrate | 90 | 25 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 84 | 37 |
| Eliquis | Apixaban | 84 | 17 |
| Alprazolam | Alprazolam | 79 | 12 |
| Mounjaro | Tirzepatide | 73 | suppressed |
| Glimepiride | Glimepiride | 67 | 17 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 67 | suppressed |
| Allopurinol | Allopurinol | 66 | 19 |
| Etodolac | Etodolac | 66 | 11 |
| Warfarin Sodium | Warfarin Sodium | 66 | 11 |
| Fluconazole | Fluconazole | 65 | 35 |
| Estradiol | Estradiol | 64 | 14 |
| Atenolol | Atenolol | 62 | 15 |
| Pregabalin | Pregabalin | 62 | 12 |
| Azithromycin | Azithromycin | 58 | 42 |
| Testosterone Cypionate | Testosterone Cypionate | 57 | 11 |
| Bupropion Xl | Bupropion Hcl | 55 | 13 |
| Fenofibrate | Fenofibrate,micronized | 55 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 55 | 13 |
| Myrbetriq | Mirabegron | 55 | suppressed |
| Topiramate | Topiramate | 53 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 52 | 13 |
| Famotidine | Famotidine | 52 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 51 | 12 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 49 | 28 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 49 | 12 |
| Fenofibrate | Fenofibrate | 49 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 49 | 19 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 48 | 36 |
| Doxazosin Mesylate | Doxazosin Mesylate | 46 | 13 |
| Glipizide Er | Glipizide | 46 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 45 | 11 |
| Benazepril Hcl | Benazepril Hcl | 44 | 13 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 44 | suppressed |
| Meloxicam | Meloxicam | 43 | 14 |
| Synthroid | Levothyroxine Sodium | 43 | 12 |
| Valacyclovir | Valacyclovir Hcl | 43 | 18 |
| Paroxetine Hcl | Paroxetine Hcl | 42 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 41 | 11 |
| Xarelto | Rivaroxaban | 41 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 40 | 25 |
| Vascepa | Icosapent Ethyl | 39 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 39 | 11 |
| Buspirone Hcl | Buspirone Hcl | 38 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 38 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 38 | 30 |
| Colchicine | Colchicine | 37 | 12 |
| Febuxostat | Febuxostat | 37 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 37 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 37 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 35 | suppressed |
| Valsartan | Valsartan | 35 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 34 | suppressed |
| Kerendia | Finerenone | 34 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 31 | 12 |
| Doxycycline Hyclate | Doxycycline Hyclate | 31 | 16 |
| Meclizine Hcl | Meclizine Hcl | 30 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 29 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 29 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 28 | 13 |
| Fenofibrate | Fenofibrate Nanocrystallized | 28 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 27 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 27 | suppressed |
| Eszopiclone | Eszopiclone | 26 | suppressed |
| Januvia | Sitagliptin Phosphate | 25 | suppressed |
| Ondansetron Odt | Ondansetron | 25 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 25 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 24 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 24 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 23 | suppressed |
| Levofloxacin | Levofloxacin | 23 | 19 |
| Bumetanide | Bumetanide | 22 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 22 | suppressed |
| Ezetimibe | Ezetimibe | 22 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 22 | suppressed |
| Nystatin | Nystatin | 22 | suppressed |
| Carvedilol | Carvedilol | 21 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 21 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 21 | suppressed |
| Naproxen | Naproxen | 21 | suppressed |
| Premarin | Estrogens, Conjugated | 21 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 21 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 21 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 21 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 20 | 17 |
| Gemtesa | Vibegron | 20 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 19 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 19 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 19 | suppressed |
| Telmisartan | Telmisartan | 19 | suppressed |
| Cephalexin | Cephalexin | 18 | 14 |
| Promethazine Hcl | Promethazine Hcl | 18 | suppressed |
| Repatha Sureclick | Evolocumab | 18 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 17 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 17 | suppressed |
| Mirtazapine | Mirtazapine | 17 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 16 | suppressed |
| Linzess | Linaclotide | 16 | suppressed |
| Minoxidil | Minoxidil | 16 | suppressed |
| Mupirocin | Mupirocin | 16 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 16 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 15 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 15 | 15 |
| Memantine Hcl Er | Memantine Hcl | 15 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 15 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 15 | 15 |
| Rybelsus | Semaglutide | 15 | suppressed |
| Vraylar | Cariprazine Hcl | 15 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 14 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 14 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 14 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 13 | suppressed |
| Spironolactone | Spironolactone | 13 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 13 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 13 | suppressed |
| Carisoprodol | Carisoprodol | 12 | suppressed |
| Ibuprofen | Ibuprofen | 12 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 12 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 12 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Ursodiol | Ursodiol | 12 | suppressed |
| Adderall Xr | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 11 | suppressed |
| Diazepam | Diazepam | 11 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 11 | suppressed |
| Memantine Hcl | Memantine Hcl | 11 | suppressed |
| Methadone Hcl | Methadone Hcl | 11 | suppressed |
| Nystop | Nystatin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,885.98 · 95 records | Novo Nordisk Inc | ABRYSVO, AIRSUPRA, Azstarys, BEXSERO, BEYFORTUS, BREZTRI, CAPVAXIVE, COMIRNATY, Cologuard Collection Kit, ENFLONSIA, FARXIGA, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, FREESTYLE LIBRE 3, GARDASIL 9, GEMTESA, GVOKE HYPOPEN, INGREZZA, JARDIANCE, KISUNLA, Kerendia, LEQVIO, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, PEDIARIX, PREVNAR 20, QULIPTA, REPATHA, REXULTI, ROTATEQ, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, TRINTELLIX, Tymlos, UBRELVY, VAXELIS, VAXNEUVANCE, VOQUEZNA, VRAYLAR, Wegovy, YUPELRI, ZAVZPRET, ZEPBOUND | 15 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error